Top

Published in:

Open Access 01-12-2018 | Original Article

Complement C3 and C4, but not their regulators or activated products, are associated with incident metabolic syndrome: the CODAM study

Authors: Ying Xin, Elisabeth Hertle, Carla J. H. van der Kallen, Casper G. Schalkwijk, Coen D. A. Stehouwer, Marleen M. J. van Greevenbroek

Published in: Endocrine | Issue 3/2018

Abstract

Purpose

We investigated the associations of components of the alternative (C3, C3a, Bb, factor D [FD], factor H [FH], properdin) and the classical complement pathway (C4, C1q, C1-inhibitor [C1-INH]) with prevalent and incident metabolic syndrome in a cohort with a moderately increased risk of cardiometabolic disease.

Methods

The study cohort was comprised of 574 participants (61% men, age 59.6 ± 7.0 years) at baseline and 489 participants after 7-year follow-up. Multiple logistic regression analyses were done to investigate the associations of concentrations of baseline plasma complement (standardized values) with prevalent and incident (in those without metabolic syndrome at baseline, n = 189) metabolic syndrome.

Results

C3 (odds ratio (OR) = 1.48 [95% confidence interval: 1.02; 2.14]) and C4 (OR = 1.95 [1.32; 2.88]), but none of the other complement components were associated with incident metabolic syndrome (n = 40 cases). Notably, in the cross-sectional analyses, we did observe higher levels of C3a (OR = 1.25 [1.03; 1.52]), FH (OR = 2.93 [2.24; 3.83]), and properdin (OR = 1.88 [1.50; 2.34]), in addition to C3 (OR = 3.60 [2.73; 4.75]) and C4 (OR = 1.39 [1.13; 1.69]), in those with the metabolic syndrome compared to those without, while no association was observed for FD, Bb, C1q, or C1-INH.

Conclusions

In the cross-sectional analyses, the effects sizes (standardized regression coefficients) for C3 and C4 were similar to those of (some of) the regulators and activators, yet only C3 and C4 were associated with incident disease. These findings suggest a role for C3 and C4, but not their regulators or activated products, in the development of the metabolic syndrome.

Available only for authorised users

S. Furukawa, T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, Y. Nakajima, O. Nakayama, M. Makishima, M. Matsuda, I. Shimomura, Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114(12), 1752–1761 (2004). https://doi.org/10.1172/jci21625 CrossRefPubMedPubMedCentral

N.S. Merle, S.E. Church, V. Fremeaux-Bacchi, L.T. Roumenina, Complement system part I—molecular mechanisms of activation and regulation. Front. Immunol. 6, 262 (2015). https://doi.org/10.3389/fimmu.2015.00262 CrossRefPubMedPubMedCentral

B.G. Gabrielsson, J.M. Johansson, M. Lonn, M. Jernas, T. Olbers, M. Peltonen, I. Larsson, L. Lonn, L. Sjostrom, B. Carlsson, L.M. Carlsson, High expression of complement components in omental adipose tissue in obese men. Obes. Res. 11(6), 699–708 (2003). https://doi.org/10.1038/oby.2003.100 CrossRefPubMed

J. Phieler, R. Garcia-Martin, J.D. Lambris, T. Chavakis, The role of the complement system in metabolic organs and metabolic diseases. Seminars in immunology 25(1), 47–53 (2013). https://doi.org/10.1016/j.smim.2013.04.003 CrossRefPubMedPubMedCentral

E. Hertle, C.D. Stehouwer, M.M. van Greevenbroek, The complement system in human cardiometabolic disease. Mol. Immunol. 61(2), 135–148 (2014). https://doi.org/10.1016/j.molimm.2014.06.031 CrossRefPubMed

R. Somani, V.R. Richardson, K.F. Standeven, P.J. Grant, A.M. Carter, Elevated properdin and enhanced complement activation in first-degree relatives of South Asian subjects with type 2 diabetes. Diabetes Care 35(4), 894–899 (2012). https://doi.org/10.2337/dc11-1483 CrossRefPubMedPubMedCentral

N. Wlazlo, M.M. van Greevenbroek, I. Ferreira, E.J. Feskens, C.J. van der Kallen, C.G. Schalkwijk, B. Bravenboer, C.D. Stehouwer, Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period: the CODAM Study. Diabetes Care 37(7), 1900–1909 (2014). https://doi.org/10.2337/dc13-2804 CrossRefPubMed

C.M. Ballantyne, R.C. Hoogeveen, A.M. McNeill, G. Heiss, M.I. Schmidt, B.B. Duncan, J.S. Pankow, Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study. Int. J. Obes. 32(Suppl 2), S21–S24 (2008). https://doi.org/10.1038/ijo.2008.31 CrossRef

R. Ajjan, A.M. Carter, R. Somani, K. Kain, P.J. Grant, Ethnic differences in cardiovascular risk factors in healthy Caucasian and South Asian individuals with the metabolic syndrome. J. Thromb. Haemost. 5(4), 754–760 (2007). https://doi.org/10.1111/j.1538-7836.2007.02434.x CrossRefPubMed

10.

A.J. van Oostrom, A. Alipour, T.W. Plokker, A.D. Sniderman, M.C. Cabezas, The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 190(1), 167–173 (2007). https://doi.org/10.1016/j.atherosclerosis.2006.01.009 CrossRefPubMed

11.

G. Meng, Q. Zhu, J. Shao, Q. Zhang, L. Liu, H. Wu, Y. Xia, X. Bao, Y. Gu, H. Wang, H. Shi, S. Sun, X. Wang, M. Zhou, Q. Jia, G. Wang, K. Song, Y. Wu, K. Niu, Comparing the diagnostic ability of inflammatory markers in metabolic syndrome. Clin. Chim. Acta 475, 1–6 (2017). https://doi.org/10.1016/j.cca.2017.09.023 CrossRefPubMed

12.

B. Nilsson, O.A. Hamad, H. Ahlstrom, J. Kullberg, L. Johansson, L. Lindhagen, A. Haenni, K.N. Ekdahl, L. Lind, C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors. Eur. J. Clin. Invest. 44(6), 587–596 (2014). https://doi.org/10.1111/eci.12275 CrossRefPubMed

13.

P.C. Wamba, J. Mi, X.Y. Zhao, M.X. Zhang, Y. Wen, H. Cheng, D.Q. Hou, K. Cianflone, Acylation stimulating protein but not complement C3 associates with metabolic syndrome components in Chinese children and adolescents. Eur. J. Endocrinol. 159(6), 781–790 (2008). https://doi.org/10.1530/eje-08-0467 CrossRefPubMed

14.

A. Onat, G. Hergenc, G. Can, Z. Kaya, H. Yuksel, Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population. Metabolism 59(5), 628–634 (2010). https://doi.org/10.1016/j.metabol.2009.09.006 CrossRefPubMed

15.

Z. Liu, Q. Tang, J. Wen, Y. Tang, D. Huang, Y. Huang, J. Xie, Y. Luo, M. Liang, C. Wu, Z. Lu, A. Tan, Y. Gao, Q. Wang, Y. Jiang, Z. Yao, X. Lin, H. Zhang, Z. Mo, X. Yang, Elevated serum complement factors 3 and 4 are strong inflammatory markers of the metabolic syndrome development: a longitudinal cohort study. Sci. Rep. 6, 18713 (2016). https://doi.org/10.1038/srep18713 CrossRefPubMedPubMedCentral

16.

N.J. Song, S. Kim, B.H. Jang, S.H. Chang, U.J. Yun, K.M. Park, H. Waki, D.Y. Li, P. Tontonoz, K.W. Park, Small molecule-induced complement factor D (adipsin) promotes lipid accumulation and adipocyte differentiation. PLoS ONE 11(9), e0162228 (2016). https://doi.org/10.1371/journal.pone.0162228 CrossRefPubMedPubMedCentral

17.

J.C. Lo, S. Ljubicic, B. Leibiger, M. Kern, I.B. Leibiger, T. Moede, M.E. Kelly, D. Chatterjee Bhowmick, I. Murano, P. Cohen, A.S. Banks, M.J. Khandekar, A. Dietrich, J.S. Flier, S. Cinti, M. Bluher, N.N. Danial, P.O. Berggren, B.M. Spiegelman, Adipsin is an adipokine that improves beta cell function in diabetes. Cell 158(1), 41–53 (2014). https://doi.org/10.1016/j.cell.2014.06.005 CrossRefPubMedPubMedCentral

18.

J.M. Moreno-Navarrete, R. Martinez-Barricarte, V. Catalan, M. Sabater, J. Gomez-Ambrosi, F.J. Ortega, W. Ricart, M. Bluher, G. Fruhbeck, S. Rodriguez de Cordoba, J.M. Fernandez-Real, Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes 59(1), 200–209 (2010). https://doi.org/10.2337/db09-0700 CrossRefPubMed

19.

D. Gauvreau, C. Roy, F.Q. Tom, H. Lu, P. Miegueu, D. Richard, W.C. Song, C. Stover, K. Cianflone, A new effector of lipid metabolism: complement factor properdin. Mol. Immunol. 51(1), 73–81 (2012). https://doi.org/10.1016/j.molimm.2012.02.110 CrossRefPubMed

20.

E. Shagdarsuren, K. Bidzhekov, Y. Djalali-Talab, E.A. Liehn, M. Hristov, R.A. Matthijsen, W.A. Buurman, A. Zernecke, C. Weber, C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice. Circulation 117(1), 70–78 (2008). https://doi.org/10.1161/circulationaha.107.715649 CrossRefPubMed

21.

M.M. van Greevenbroek, I.C. Arts, C.J. van der Kallen, P.C. Dagnelie, I. Ferreira, E. Jansen, C.G. Schalkwijk, E.J. Feskens, C.D. Stehouwer, Complement c3 is inversely associated with habitual intake of provitamin A but not with dietary fat, fatty acids, or vitamin E in middle-aged to older white adults and positively associated with intake of retinol in middle-aged to older white women. J. Nutr. 144(1), 61–67 (2014). https://doi.org/10.3945/jn.113.181628 CrossRefPubMed

22.

E. Hertle, I.C. Arts, C.J. van der Kallen, E.J. Feskens, C.G. Schalkwijk, C.D. Stehouwer, M.M. van Greevenbroek, The alternative complement pathway is longitudinally associated with adverse cardiovascular outcomes. The CODAM study. Thromb. Haemost. 115(2), 446–457 (2016). https://doi.org/10.1160/th15-05-0439 CrossRefPubMed

23.

E. Hertle, M.M. van Greevenbroek, I.C. Arts, C.J. van der Kallen, E.J. Feskens, C.G. Schalkwijk, C.D. Stehouwer, Complement activation products C5a and sC5b-9 are associated with low-grade inflammation and endothelial dysfunction, but not with atherosclerosis in a cross-sectional analysis: the CODAM study. Int. J. Cardiol. 174(2), 400–403 (2014). https://doi.org/10.1016/j.ijcard.2014.04.057 CrossRefPubMed

24.

S.P. Dillon, A. D’Souza, B.T. Kurien, R.H. Scofield, Systemic lupus erythematosus and C1q: a quantitative ELISA for determining C1q levels in serum. Biotechnol. J. 4(8), 1210–1214 (2009). https://doi.org/10.1002/biot.200800273 CrossRefPubMedPubMedCentral

25.

K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato, J.C. Fruchart, W.P. James, C.M. Loria, S.C. Smith Jr., Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16), 1640–1645 (2009). https://doi.org/10.1161/circulationaha.109.192644 CrossRefPubMed

26.

M.M. van Greevenbroek, M. Jacobs, C.J. van der Kallen, E.E. Blaak, E.H. Jansen, C.G. Schalkwijk, E.J. Feskens, C.D. Stehouwer, Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM study). Int. J. Cardiol. 154(2), 158–162 (2012). https://doi.org/10.1016/j.ijcard.2010.09.017 CrossRefPubMed

27.

N. Wlazlo, M.M. van Greevenbroek, I. Ferreira, E.H. Jansen, E.J. Feskens, C.J. van der Kallen, C.G. Schalkwijk, B. Bravenboer, C.D. Stehouwer, Activated complement factor 3 is associated with liver fat and liver enzymes: the CODAM study. Eur. J. Clin. Invest. 43(7), 679–688 (2013). https://doi.org/10.1111/eci.12093 CrossRefPubMed

28.

A. Lonardo, S. Ballestri, G. Marchesini, P. Angulo, P. Loria, Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig. Liver Dis. 47(3), 181–190 (2015). https://doi.org/10.1016/j.dld.2014.09.020 CrossRefPubMed

29.

S. Devaraj, U. Singh, I. Jialal, Human C-reactive protein and the metabolic syndrome. Curr. Opin. Lipidol. 20(3), 182–189 (2009). https://doi.org/10.1097/MOL.0b013e32832ac03e CrossRefPubMedPubMedCentral

30.

S. Jain, V. Gautam, S. Naseem, Acute-phase proteins: as diagnostic tool. J. Pharm. Bioallied Sci. 3(1), 118–127 (2011). https://doi.org/10.4103/0975-7406.76489 CrossRefPubMedPubMedCentral

31.

S. I. Vlaicu, A. Tatomir, D. Boodhoo, S. Vesa, P. A. Mircea, H. Rus, The role of complement system in adipose tissue-related inflammation. Immunol. Res. (2016). https://doi.org/10.1007/s12026-015-8783-5 CrossRef

32.

R.M. Al Haj Ahmad, H.A. Al-Domi, Complement 3 serum levels as a pro-inflammatory biomarker for insulin resistance in obesity. Diabetes Metab. Syndr. 11(Suppl 1), S229–S232 (2017). https://doi.org/10.1016/j.dsx.2016.12.036 CrossRefPubMed

33.

A. Muscari, S. Antonelli, G. Bianchi, G. Cavrini, S. Dapporto, A. Ligabue, C. Ludovico, D. Magalotti, G. Poggiopollini, M. Zoli, Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care 30(9), 2362–2368 (2007). https://doi.org/10.2337/dc07-0637 CrossRefPubMed

34.

J. Warnberg, E. Nova, L.A. Moreno, J. Romeo, M.I. Mesana, J.R. Ruiz, F.B. Ortega, M. Sjostrom, M. Bueno, A. Marcos, Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population: the AVENA study. Am. J. Clin. Nutr. 84(3), 505–512 (2006). https://doi.org/10.1093/ajcn/84.3.505 CrossRefPubMed

35.

M. Kolev, S. Dimeloe, G. Le Friec, A. Navarini, G. Arbore, G.A. Povoleri, M. Fischer, R. Belle, J. Loeliger, L. Develioglu, G.R. Bantug, J. Watson, L. Couzi, B. Afzali, P. Lavender, C. Hess, C. Kemper, Complement regulates nutrient influx and metabolic reprogramming during Th1 cell responses. Immunity 42(6), 1033–1047 (2015). https://doi.org/10.1016/j.immuni.2015.05.024 CrossRefPubMedPubMedCentral

36.

M.K. Liszewski, M. Kolev, G. Le Friec, M. Leung, P.G. Bertram, A.F. Fara, M. Subias, M.C. Pickering, C. Drouet, S. Meri, T.P. Arstila, P.T. Pekkarinen, M. Ma, A. Cope, T. Reinheckel, Cordoba,S. Rodriguez de, B. Afzali, J.P. Atkinson, C. Kemper, Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 39(6), 1143–1157 (2013). https://doi.org/10.1016/j.immuni.2013.10.018 CrossRefPubMedPubMedCentral

37.

X. Liu, C. Jiang, P. Yang, Association of single nucleotide polymorphisms in the 5′ upstream region of the C4BPA gene with essential hypertension in a northeastern Han Chinese population. Mol. Med. Rep. 16(2), 1289–1297 (2017). https://doi.org/10.3892/mmr.2017.6736 CrossRefPubMedPubMedCentral

38.

J. Sjolander, E. Byman, K. Kulak, S.C. Nilsson, E. Zhang, U. Krus, G.T. Westermark, P. Storm, B.C. King, E. Renstrom, A.M. Blom, C4b-binding protein protects beta-cells from islet amyloid polypeptide-induced cytotoxicity. J. Biol. Chem. 291(41), 21644–21655 (2016). https://doi.org/10.1074/jbc.M116.731141 CrossRefPubMedPubMedCentral

39.

H. Wang, D. Ricklin, J.D. Lambris, Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proc. Natl Acad. Sci. USA 114(41), 10948–10953 (2017). https://doi.org/10.1073/pnas.1707364114 CrossRefPubMed

40.

S. Antoniak, J.C. Cardenas, L.J. Buczek, F.C. Church, N. Mackman, R. Pawlinski, Protease-activated receptor 1 contributes to angiotensin II-induced cardiovascular remodeling and inflammation. Cardiology 136(4), 258–268 (2017). https://doi.org/10.1159/000452269 CrossRefPubMed

41.

S. Lienenklaus, R.S. Ames, M.A. Tornetta, H.M. Sarau, J.J. Foley, T. Crass, B. Sohns, U. Raffetseder, M. Grove, A. Holzer, A. Klos, J. Kohl, W. Bautsch, Human anaphylatoxin C4a is a potent agonist of the guinea pig but not the human C3a receptor. J. Immunol. 161(5), 2089–2093 (1998)PubMed

42.

Z. Xia, A.D. Sniderman, K. Cianflone, Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob mice. J. Biol. Chem. 277(48), 45874–45879 (2002). https://doi.org/10.1074/jbc.M207281200 CrossRefPubMed

43.

Yiannis N. Kallis, Christopher J. Scotton, Alison C. MacKinnon, Robert D. Goldin, Nicholas A. Wright, John P. Iredale, Rachel C. Chambers, Stuart J. Forbes, Simon Afford, Proteinase Activated Receptor 1 Mediated Fibrosis in a Mouse Model of Liver Injury: A Role for Bone Marrow Derived Macrophages. PLoS ONE 9(1), e86241 (2014).CrossRef

Title: Complement C3 and C4, but not their regulators or activated products, are associated with incident metabolic syndrome: the CODAM study
Authors: Ying Xin
Elisabeth Hertle
Carla J. H. van der Kallen
Casper G. Schalkwijk
Coen D. A. Stehouwer
Marleen M. J. van Greevenbroek
Publication date: 01-12-2018
Publisher: Springer US
Published in: Endocrine / Issue 3/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1712-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Ectopic thyroids have lower computed tomography attenuation values than orthotopic thyroids

30mCi radioactive iodine achieving comparative excellent response in intermediate/high-risk nonmetastatic papillary thyroid cancer: a propensity score matching study

SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival

Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3

Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting

Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials